FY103B Identified to Exhibit Profound Antineoplastic Effects in the Digestive Tract
12/10/14 10:30 Filed in: innovations | drug discovery | pharmaceutical company | cancer | FY103B | superior | NSAID | ibuprofen | intestinal
Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category.
Wilmington, DE
Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category.
FY103B was found to exhibit significant reductions in the risk of developing oesophageal, stomach, and intestinal cancers. In studies, FY103B demonstrated profound anti-neoplastic activity by suppressing a unique panel of mediators that are involved in cancer. The effects of FY103B was found to be significantly superior in terms of efficacy and safety to controls which included market comparators.
FY103B was identified by FyMed through a proprietary drug discovery process denoted the Fy10 technology, and further developed through extensive mechanism of action studies that integrates advanced pharmacogenomics and proteomics. FyMed applies integrated molecular phenotypic based innovative approaches in studies with companion prognostic driven drug-centric modalities.
About FyMed
FyMed, Inc. is a pharmaceutical company with a growing portfolio of novel and improved pharmaceuticals developed and enhanced through targeted use of next-generation proteomic and genomic technologies in drug discovery and development. Leading innovations in precision medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively capitalize on key market deficiencies.
Safe Harbor Statement
To the extent any statements made in this document contain information that is not historical, this news release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words "intends," "plans," "will," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described herein. These risks and uncertainties may include, without limitation, projected expansions, outcomes of our clinical trials, achievement of our business objectives, and the ability to obtain necessary regulatory approvals. FyMed undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.
Contact:
Media Relations, FyMed, Inc.
3422 Old Capitol, Suite 1610
Wilmington, DE 19808
Tel: 302-722-5010
Email: media@fymed.com
http://www.fymed.com/media.html
Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category.
FY103B was found to exhibit significant reductions in the risk of developing oesophageal, stomach, and intestinal cancers. In studies, FY103B demonstrated profound anti-neoplastic activity by suppressing a unique panel of mediators that are involved in cancer. The effects of FY103B was found to be significantly superior in terms of efficacy and safety to controls which included market comparators.
FY103B was identified by FyMed through a proprietary drug discovery process denoted the Fy10 technology, and further developed through extensive mechanism of action studies that integrates advanced pharmacogenomics and proteomics. FyMed applies integrated molecular phenotypic based innovative approaches in studies with companion prognostic driven drug-centric modalities.
About FyMed
FyMed, Inc. is a pharmaceutical company with a growing portfolio of novel and improved pharmaceuticals developed and enhanced through targeted use of next-generation proteomic and genomic technologies in drug discovery and development. Leading innovations in precision medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively capitalize on key market deficiencies.
Safe Harbor Statement
To the extent any statements made in this document contain information that is not historical, this news release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words "intends," "plans," "will," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described herein. These risks and uncertainties may include, without limitation, projected expansions, outcomes of our clinical trials, achievement of our business objectives, and the ability to obtain necessary regulatory approvals. FyMed undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.
Contact:
Media Relations, FyMed, Inc.
3422 Old Capitol, Suite 1610
Wilmington, DE 19808
Tel: 302-722-5010
Email: media@fymed.com
http://www.fymed.com/media.html